We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App





Cepheid Demonstrates Advantages of PCRplus Solution at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: PCRplus tests deliver rapid, accurate and actionable respiratory results (Photo courtesy of Cepheid)
Image: PCRplus tests deliver rapid, accurate and actionable respiratory results (Photo courtesy of Cepheid)

Cepheid (Sunnyvale, CA, USA) will be demonstrating the advantages of its PCRplus Solution at the 2022 AACC Clinical Lab Expo. PCRplus is an elevated PCR test category reserved for molecular diagnostic testing solutions that deliver uncompromised accuracy, speed, flexibility, simplicity, and exceptional test design expertise.

The PCRplus Solution comprises one platform and 22 IVD tests that combine accuracy, speed, flexibility, quality, and simplicity. Cepheid offers a growing portfolio of PCRplus respiratory tests that run on its 40,000 GeneXpert systems placed worldwide to deliver rapid, accurate, and actionable respiratory results. The GeneXpert System was built for simple, reference lab quality PCR testing – on location at medical centers and hospitals or closer to patient in health clinics and nursing homes. At the core of every GeneXpert System is the module (or testing bay) where a test cartridge is loaded onto the machine.

Cepheid’s line of GeneXpert Systems can be configured with a varying number of modules, or test bays, to meet the volume requirements of any setting. Smaller GeneXpert Systems are configured with two or four modules – meaning up to four different tests can be run at one time. The company’s largest GeneXpert System is configured with up to 80 modules – meaning as many as 80 tests can operate independently at any given time with a capacity of about 2,000 tests per day.

Cepheid offers CoV-2 tests that are designed with multiple gene targets to ensure comprehensive virus detection. This test design approach is used in all of Cepheid's Xpert CoV-2 tests to help guard against variants and ensure the test performance healthcare providers have come to rely on. The company has added the latest Xpert Xpress CoV-2plus test to Xpert Xpress CoV-2/Flu/RSV plus and others in its growing portfolio of PCRplus-based Xpert coronavirus tests.
 

Related Links:
Cepheid

New
Gold Member
Chagas Disease Test
CHAGAS Cassette
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Nephelometer
F-TC2015
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.